Grown Rogue International (GRUSF) Interest Expenses (2009 - 2026)
Grown Rogue International (GRUSF) recorded quarterly Interest Expenses of $549980.0 in Q1 2026, down 100.0% quarter-over-quarter from $400.9 billion in Q4 2025, and up 113.03% on a YoY basis from $258171.0 in Q1 2025.
Grown Rogue International (GRUSF) Interest Expenses (2009 - 2026) Analysis & Trends
Grown Rogue International's Interest Expenses history runs 17 years deep, the most recent figure standing at $549980.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 113.03% year-over-year to $549980.0; the TTM figure through Mar 2026 stood at $275.7 billion (up 371.02% YoY), while the FY2025 annual figure was $150331.0, up 93.94% from the prior year.
- Interest Expenses was $549980.0 for Q1 2026 at Grown Rogue International, down from $400.9 billion in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $400.9 billion in Q4 2025 to a low of -$125.2 billion in Q3 2025.
- Historically, Interest Expenses has averaged $12.4 billion across 5 years, with a median of -$96783.5 in 2023.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses sank 1244.67% in 2022, then surged 387.86% in 2025.
- A 5-year view of Interest Expenses shows it stood at -$114660.0 in 2022, then soared by 160.32% to $69164.0 in 2023, then tumbled by 147102638.89% to -$101.7 billion in 2024, then soared by 494.07% to $400.9 billion in 2025, then plunged by 100.0% to $549980.0 in 2026.
- The last three Interest Expenses figures came in at $549980.0 (Q1 2026), $400.9 billion (Q4 2025), and -$125.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 62.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 3.00 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 20.89 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 4.86 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Grown Rogue International | - | - | 3.96 Mn | 549,980.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 549,980.00 |
| Mar 31, 2026 | 549,980.00 |
| Dec 31, 2025 | 400.94 Bn |
| Dec 31, 2025 | 400.94 Bn |
| Sep 30, 2025 | -125.20 Bn |
| Sep 30, 2025 | -125.20 Bn |
| Jun 30, 2025 | -157,283.00 |
| Jun 30, 2025 | -157,283.00 |
| Mar 31, 2025 | 258,171.00 |
| Mar 31, 2025 | 258,171.00 |
| Sep 30, 2024 | -101.74 Bn |
| Sep 30, 2024 | -101.74 Bn |
| Jun 30, 2024 | -58,225.11 |
| Jun 30, 2024 | -58,225.11 |
| Mar 31, 2024 | -89,687.00 |
| Mar 31, 2024 | -89,687.00 |
| Dec 31, 2023 | 69,164.00 |
| Dec 31, 2023 | 69,164.00 |
| Oct 31, 2023 | -271,112.00 |
| Oct 31, 2023 | -271,112.00 |